SRP RESEARCH LIBRARY · EVIDENCE GUIDE
Eloralintide (LY3841136) Research Guide
Understand the amylin receptor research, distinguish laboratory findings from clinical trials, and review the limits of what published studies establish.
Sources checked October 9, 2026. Educational summary, not medical advice or a complete systematic review.
What is Eloralintide?
Eloralintide, also identified as LY3841136, is an amylin analogue studied for receptor selectivity and metabolic effects. The discovery study compared human and rat AMY1R, AMY3R and calcitonin receptors. Preferential activation of human AMY1R was reported; the rat receptor profile differed. Findings therefore need to be read in the context of the assay and species. Discovery and receptor-characterization study.
How the research connects
1. Receptor assays
Compare activity at AMY1R, AMY3R and the calcitonin receptor using cellular signaling measurements, including cAMP.
2. Preclinical models
Study food intake, body composition and exposure in animal models. These observations do not establish a human outcome.
3. Controlled clinical studies
Evaluate trial-manufactured material in defined participant groups with monitoring and prespecified outcomes.
This is an explanatory pathway map, not experimental data or a claim that SRP inventory was used in these studies.
Published human evidence
Phase 1
A 2026 publication describes a 12-week randomized, placebo-controlled study involving 100 participants. It examined safety, tolerability, pharmacokinetics and pharmacodynamic responses. Early-phase findings have limits and should not be treated as instructions for personal use.
Phase 2
The 48-week randomized trial enrolled 263 participants at 46 US research centres. It reported bodyweight reductions, with nausea and fatigue among the most common adverse events. The population excluded type 2 diabetes. Eli Lilly funded the trial, and the paper reports author conflicts of interest.
What these studies do not establish
Publication of a study does not authenticate a commercial vial or establish its purity, sterility, stability or equivalence to clinical-trial material. Those questions require evidence for the specific batch. A research product listing is not a prescription or an approved treatment.
Questions to ask when reviewing a research vial
- Does the supplied report identify the same compound and lot?
- Which analytical methods were used, and what did each actually measure?
- Are storage and stability statements supported for this material?
- Are conclusions from cells, animals or a defined human trial?
SRP product information
The SRP listing is a 20 mg lyophilized research vial. This amount describes total vial content, not a recommended dose. Current price, availability and product specifications belong on the product page.
View Eloralintide 20 mgReturn to the Research Library
Laboratory research only. Not for human or animal consumption, administration, medical or therapeutic use.